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Background: Patient adherence to isoniazid (INH) monotherapy for latent tuberculosis infection (LTBI) has been
suboptimal despite its proven efficacy. Various strategies have been studied to improve adherence, but all have
been based at a clinic or treatment program. At the Santa Clara Valley Tuberculosis Clinic, it was our practice to
refer a subset of high-risk LTBI patients to the Public Health Department for monthly follow-up at home instead of
at the clinic. Our goal was to assess whether house calls by community health workers and public health nurses
affected INH adherence or frequency of adverse effects.
Methods: We retrospectively studied 3918 LTBI patients who received INH. At the discretion of the treating
physician, 986 (25.2%) received house calls instead of clinic follow-up. Home-based follow-up included language
translation, medication delivery, assessment of compliance with pill counts, monitoring for adverse effects, and
active tracking of noncompliant patients. We assessed differences in patient characteristics, treatment completion,
and reasons for treatment discontinuation between patients followed at home versus in the clinic. Multivariate
analyses to address possible referral bias or confounding were performed using logistic regression.
Results: More patients followed with house calls completed INH treatment (90% home versus 73.2% clinic). This
was the case across all subgroups of patients, including those with historically the lowest adherence: patients from
correctional and rehabilitation facilities (77.8% home versus 46.9% clinic), postpartum women (86.4% home versus
55.6% clinic), and patients aged between 18 and 35 years (87% home versus 63.1% clinic). After adjusting for age,
place of birth, referral category (TB contacts/skin test converters, correctional/rehabilitation patients, postpartum
women, tuberculin positive patients from other screening), and prescribed INH regimen duration (9 versus 6
months), home-based follow-up of LTBI patients was a significant predictor of treatment completion (AOR 2.94,
95% CI: 2.33, 3.71). Patients followed at home were 21% more likely to complete therapy (ARR 1.21, p<0.001). Risk of
adverse effects was similar between the two types of follow-up.
Conclusion: Home-based follow-up of LTBI patients taking isoniazid was associated with improved treatment
completion and no increase in adverse effects regardless of patient characteristics or prescribed duration of INH
therapy.
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Targeted screening for latent tuberculosis infection
(LTBI) followed by treatment with isoniazid (INH) is an
important facet of tuberculosis (TB) control programs
in the US [1]. Studies have shown that LTBI treatment
with INH is 69% to 93% effective in preventing the de-
velopment of active TB, but effectiveness depends
greatly on the level of adherence [2-4]. The U.S. Centers
for Disease Control and Prevention set the target com-
pletion rate in high-risk individuals at 85% [5]. In most
clinic settings, however, completion of LTBI treatment
falls significantly short of this goal and ranges from 47%
to 60% [6,7]. Various strategies to improve LTBI treat-
ment adherence have been evaluated for different high-
risk groups but none has proven effective across the
board [6,8-10]. In Santa Clara County, California, many
of the LTBI patients are recent immigrants or refugees
who have significant social obstacles to receiving and
completing INH treatment. In an effort to improve
adherence for patients at high risk of treatment failure,
the Santa Clara County Tuberculosis Clinic used a strat-
egy that involved public health nurses assessing a subset
of LTBI patients in their homes every month for the
duration of treatment. To assess the efficacy of this
approach, we conducted a retrospective evaluation of
the effect of house calls on INH treatment completion
and incidence of adverse effects.
Methods
Study site and patients
The Santa Clara County Tuberculosis Clinic is a pub-
licly funded TB referral center. The study included all
LTBI patients with positive tuberculin skin tests (TST+)
and normal chest radiographs who began INH treat-
ment from January 1, 2000 to December 31, 2002.
Patients were referred from community physicians; im-
migration services; correctional and rehabilitation facil-
ities; school, work, antenatal, and homeless shelter
screening; and Public Health Department contact inves-
tigations. Patients who discontinued INH due to
unavoidable reasons (pregnancy, index case with INH-
resistant TB, death from unrelated causes, patient
relocation) were excluded. The Investigational Review
Board at the Santa Clara Valley Medical Center granted
a waiver for the study and gave ethical approval for
publication of the results.
INH treatment and follow-up
INH treatment consisted of 300-milligram (mg) daily
tablets in adults and doses of 10 to 15 mg/kilogram/day in
children. During the study period, there was an overlap of
both 6 and 9 months of INH prescriptions as new recom-
mendations from the Centers for Disease Control and
Prevention took effect [1]. At the discretion of the treatingphysician, patients who were identified at increased risk
for not completing INH treatment, and in particular high
TB-risk patients (children younger than six, contacts
to TB cases, and TST converters) were assigned to
monthly home follow-up instead of monthly clinic
visits. Both community health workers, who assisted
with medication delivery, translation, and assessment of
compliance, and public health nurses, who monitored
adverse effects and conducted active tracking of non-
compliant patients, performed house calls. Patients
experiencing side effects returned to the clinic for
evaluation while continuing home-based follow-up.
Compliance was assessed by clinic attendance (for those
with clinic follow-up), pill count, and number of INH
refills received. Patients who failed three consecutive
appointments were considered lost to follow-up. Comple-
tion of therapy was defined by receiving at least 6 months
of INH within 9 months of time. We chose this definition
because taking at least 6 months of INH is 69% protective
against active TB [2].
For patients taking other medications with known hep-
atotoxicity or with co-morbidities such as chronic viral
hepatitis or alcohol abuse, baseline and monthly liver
function tests (LFTs) were ordered at the discretion of the
physician. INH treatment was stopped if significant
adverse reactions developed or if patients became preg-
nant. Individual charts were reviewed for patients who
stopped treatment due to abnormal LFTs. The definition
of definite INH-related hepatitis was an alanine amino-
transferase three times the upper limit of normal with
accompanying symptoms or five times the upper limit of
normal regardless of symptoms [11].
Analysis
Main outcome measures were proportions of patients
completing INH treatment and of patients developing
adverse effects among those followed at home versus at
the clinic. Differences in proportions were analyzed
with the Chi-square and Fisher’s exact tests. Differences
in means and distributions were compared using the
t-test or the Wilcoxon rank-sum test as appropriate.
Multivariate analyses were conducted using logistic
regression. Variables that approached statistical signifi-
cance in univariate analyses (p<0.20) were tested in
multivariate models. Adjusted relative risks (RR) were
calculated from the adjusted odds ratios using the pro-
cedure described by Zhang and Yu [12]. Confidence
intervals for the RRs were estimated using the substitu-
tion method [13]. Risk of adverse reactions and INH-
hepatitis were analyzed using multivariate logistic
regression. Analyses were performed using SAS statis-
tical software (version 9.3, SAS Institute, Cary, North
Carolina). Multiple comparisons were addressed using
the Hochberg adjustment [14].
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Patient characteristics
A total of 3918 TST+ patients with normal chest radio-
graphs were prescribed INH; 25.2% were assigned to have
home-based follow-up while the remaining 74.8% received
solely clinic-based follow-up (Table 1). Most patients were
foreign-born (87.2%). The three most frequent countries
of origin were Mexico (50.4%), Vietnam (10.2%), and the
Philippines (8.2%). There were more children under six
years of age in the house call group, as well as more pa-
tients who were TST converters and TB case contacts. In
contrast, very few patients from correctional and rehabili-
tation facilities were assigned to have house calls (0.9%).
The need for translation services was similar for all pa-
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fPatients from correctional and drug and alcohol rehabilitation facilities.
gWomen treated more than 2 months after delivery of child.
hTST+: Tuberculin skin test positive from routine screening.
i Nine months of isoniazid as opposed to six months of isoniazid.INH treatment completion
The proportion of patients completing at least 6 months
of INH ranged from 46.9% to 95.7% depending on patient
category (Table 2). The highest non-adherence was seen
in patients from correctional and rehabilitation facilities
and in postpartum women. The age group 18 to 35 had
the highest noncompliance. With home follow-up, com-
pletion improved across all subgroups of patients. In the
multivariate analysis, the final explanatory variables of
treatment completion were type of follow-up (home vs.
clinic), duration of INH regimen (9 months vs. 6 months),
age (<6, 6 to <18, 18 to <35, and 35 and older), patient re-
ferral reason (TB contact/TST converter, correctional pa-
tient, postpartum patient, and all other TST reactors), and
region of birth. After adjusting for these variables, patientsfection
6) Clinic follow-upb (N=2932) p-
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lic health nurse.
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is cases.
Table 2 Latent tuberculosis patients completing INH treatment, stratified by type of follow-up
Home follow-upa N=986 Clinic follow-upb N=2932
Patient characteristic Completedc (%)d Completed (%) p-valuee Risk ratiof
All patients 887 (90.0) 2147 (73.2) <0.001g 1.23
Female 500 (91.1) 1068 (72.8) 0.99 1.25
Age categories: <0.001
Age<6 135 (95.7) 129 (92.1) 1.04
Age 6 to <18 258 (93.1) 813 (84.1) 1.11
Age 18 to <35 347 (87.0) 685 (63.1) 1.38
Age 35 and older 147 (87.0) 520 (70.3) 1.24
Place of birth: <0.001
Latin America 526 (88.9) 1124 (71.5) 1.24
Asia 227 (93.4) 652 (77.9) 1.20
USA 66 (88.0) 185 (69.0) 1.28
Africa 21 (95.5) 34 (70.8) 1.35
Europe 19 (95.0) 66 (80.5) 1.18
Unknown 28 (82.4) 86 (69.4) 1.19
Patient referral reason: <0.001
Correctional/rehabilitationh 7 (77.8) 106 (46.9) 1.66
TST converters/TB contactsi 199 (90.5) 177 (77.3) 1.17
Postpartum women 51 (86.4) 94 (55.6) 1.55
TST+j from screening 630 (90.3) 1770 (76.9) 1.17
Prescribed 9 months isoniazidk 508 (91.5) 1226 (76.9) <0.001 1.19
aPatients assigned home-based follow-up with community health workers and public health nurses.
bPatients with only clinic-based follow-up.
cCompleted at least 6 months of isoniazid.
dPercentage of number completed over total number in category, listed in Table 1.
eCochran-Mantel-Haenszel test except as noted, all p-values adjusted for multiple comparisons.
fUnadjusted “risk” ratio of completing treatment of home versus clinic follow-up for each patient category.
gChi-square test.
hPatients from correctional and drug and alcohol rehabilitation facilities.
iRecent tuberculin skin test converters and household contacts to active tuberculosis cases.
jTST+: Tuberculin skin test positive.
kPrescribed 9 months instead of 6 months of isoniazid.
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health workers had a three-fold increase in the odds of
treatment completion compared to those followed in the
clinic. This adjusted odds ratio corresponded to a 21% in-
crease in the probability of completing INH treatment for
patients with home visits (Table 3). To better understand
why patients failed to complete at least six months of
INH, we examined the reasons for INH discontinuation
according to the type of follow-up assigned (Table 4) and
found that those assigned to house calls were much less
likely to refuse to continue treatment (7.6% versus 23.2%
clinic follow-up, p <0.001).
Adverse reactions leading to INH discontinuation
There were few adverse reactions requiring treatment
discontinuation. These included abnormal LFTs, ab-
dominal pain, nausea, rash, headache, dizziness, andfatigue (Table 4). The occurrence of adverse events was
3.3% for the entire cohort and similar between the two
types of follow-up. We adjusted for age (<35 years
vs. ≥35 years), and postpartum status (yes vs. no). Age
35 was chosen as the cut-off to reflect the historical age
threshold used to determine whether INH should be
offered to TST+ patients who were at low risk for TB
reactivation [15]. There was no association between
adverse events and type of patient follow-up after
adjusting for age and referral reason (AOR 0.72, 95% CI
0.46-1.14, p=0.16).
Abnormal LFTs were infrequent, but more common in
clinic follow-up patients (1.4% vs 0.3% house calls,
p=0.02). Many of these patients had abnormal LFTs
prior to starting INH. Development of definite INH-
related hepatitis (not due to pre-existing viral hepatitis,
for example) was rare, and occurred in only 1 (0.1%)
Table 3 Factors associated with completion of at least 6 months of isoniazid treatment
Risk factor ORa 95% CL AORb 95% CL ARRc 95% CLd
Home follow-upe 3.27 2.62 4.09 2.94 2.33 3.71 1.21 1.18 1.24
9 months of isoniazid 1.50 1.29 1.74 0.88 0.73 1.05 0.97 0.92 1.01
Female 1.04 0.89 1.21
Age categories:
Age<6 6.80 4.11 11.25 5.40 3.19 9.13 1.07 1.06 1.08
Age 6 to <18 2.71 2.23 3.30 2.64 2.10 3.32 1.11 1.09 1.12
Age 18 to <35 ref ref ref
Age 35 and older 1.21 1.00 1.45 1.18 0.96 1.44 1.05 0.99 1.10
Patient referral reason:
Correctional/rehabilitation 0.23 0.18 0.31 0.43 0.32 0.57 0.59 0.47 0.71
TST converters/TB contactsf 1.30 0.99 1.70 1.23 0.93 1.63 1.04 0.98 1.10
Postpartum women 0.44 0.33 0.59 0.64 0.47 0.87 0.80 0.67 0.94
TST+g from screening ref ref ref
Place of birth:
Africa 1.34 0.72 2.50 1.29 0.67 2.49 1.07 0.87 1.21
Asia 1.60 1.21 2.13 1.62 1.18 2.22 1.09 1.03 1.14
Europe 1.83 1.03 3.25 1.93 1.06 3.53 1.10 1.01 1.16
Latin America 1.17 0.91 1.52 1.25 0.93 1.67 1.06 0.98 1.13
Unknown 0.95 0.62 1.45 1.06 0.67 1.68 1.02 0.87 1.14
USA ref ref ref
aAnalysis by logistic regression.
bAdjusted OR. Multivariate model included: type of follow-up, regimen, age (categories), patient referral reason, and place of birth.
cAdjusted Risk Ratio, calculated from adjusted OR.
dAdjusted Risk Ratio 95% confidence limits, calculated from adjusted OR.
eHome-based follow-up with public health nurses and community health workers.
fTuberculin skin test converters or contacts of cases with active tuberculosis.
gTST+: Tuberculin skin test positive.






N=986 (%) N=2932 (%)
Adverse reaction 24 (2.4) 105 (3.6) 0.24
Abnormal liver enzymesd 3 (0.3) 40 (1.4) 0.02
INH –related hepatitise 1 (0.1) 23 (0.8) 0.06f
Rash 7 (0.7) 30 (1.0) 0.58
Other symptomsg 14 (1.4) 35 (1.2) 0.58
Refused/Losth 75 (7.6) 680 (23.2) <0.001
aHome-based follow-up with community health workers and public
health nurses.
bClinic-based follow-up.
cAnalysis by chi-square or Fisher’s exact test, adjusted for
multiple comparisons.
dAny abnormality of liver enzymes associated with treatment discontinuation.
eSubset of patients with abnormal liver enzymes with isoniazid-related
hepatitis, based on chart review.
fp-value for INH-related hepatitis only.
gAny other intolerable symptom that necessitated treatment discontinuation
such as headache, dizziness, fatigue, among others.
hRefused to continue treatment or were lost to follow-up.
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clinic follow-up (p=0.06). The incidence of hepatitis due
to INH was 0.4% in patients younger than 35 and 1.3%
in those 35 and older. Women aged 18 to 35 who were
treated with INH after childbirth appeared to have simi-
lar incidence of hepatitis to other age-matched women
(1.9% vs. 1.0%, p=0.29). After adjusting for age and post-
partum state, there was a trend towards decreased INH-
related hepatitis in the patients with home follow-up
(AOR 0.15, 95% CI: 0.02-1.08, p=0.06).Discussion
INH monotherapy remains the mainstay of LTBI treat-
ment, and adherence will continue to be a significant
concern due to the long duration of therapy. Four
months of rifampin is an alternate regimen for LTBI that
is of shorter duration, has higher patient adherence than
9 months of INH [16,17], and is likely more cost-
effective [18]. However, efficacy studies of rifampin
versus INH are limited [19]. Recently, a 3-month regi-
men of INH and rifapentine once weekly with DOT had
very high patient adherence and similar efficacy as 6 or
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tive patients. However, this regimen is not recommended
for young children, HIV patients on antiretroviral ther-
apy, or pregnant women [22]. The medications alone are
also 16 times more expensive than INH and although
the regimen may be cost-effective or cost-saving at the
societal level [23], it could be difficult in resource-
limited settings.
Our study demonstrates that house calls may be an
effective method to increase INH treatment adherence
to the U.S. national target of 85%. Several strategies to
improve treatment adherence have been examined in
the past. These have included the use of cultural case-
management, education, peer support, financial incen-
tives, direct observed therapy (DOT), and active tracking
of patients at high risk of failing to complete treatment
[6,24]. Some of the strategies reported, such as coupling
DOT with methadone treatment [1], are very specific for
the intended patient cohort and are less useful in other
populations. Non-physician health workers such as phar-
macists [9] or case-manager nurses [25,26] have also
been found effective in following LTBI patients. However
all of the interventions studied to date have been clinic-
based. House calls to LTBI patients constitute a method
that could be applied across many types of patient
populations.
One of the limitations of the study was the non-
randomized method of assigning patients to receive
either house calls or clinic follow-up. The assignment
reflected current practice in our clinic and relied on the
experience and discretion of the physician and nurse
practitioner. It is clear from the different distribution of
patient characteristics (Table 1) that clinicians consid-
ered the patient’s age, risk of failing to complete treat-
ment, and risk of progression to active tuberculosis
when choosing the type of follow-up, and this may have
introduced bias or confounding into the study. For
example, it is possible that TB contacts are more likely
to complete treatment because of patients’ perception of
risk, and these patients were also more likely to be
assigned home follow-up, particularly because the index
case could also be receiving DOT at home. Arguing
against this was the finding that TB contacts and routine
TST+ patients had similar completion rates within each
type of follow-up (Table 2). For example, both TB
contacts and TST+ patients from screening had 77%
completion with clinic follow-up versus 90% with house
calls. Instead, awareness of insufficient resources and
staffing might have biased physicians into assigning
fewer high-risk patients for home follow-up than they
might have otherwise. It was also our practice to refer
high-risk patients who missed three clinic appoint-
ments to have home follow-up, thereby biasing the
home follow-up group with patients more likely tofail treatment completion. Therefore, it is also pos-
sible that the true effect of house calls on INH
adherence was attenuated. Because patient character-
istics between the groups were different, we made an
effort to address possible confounders with multivari-
ate analysis. We recognize that residual confounding
may remain. For example, there were more patients
with abnormal liver enzymes in the clinic follow-up
group. This could be explained by a tendency to keep
patients with comorbidities in the clinic or a lower
threshold for clinic physicians to elicit symptoms and
test for liver abnormalities that might otherwise have
gone undetected. We acknowledge these limitations
of our study. A randomized clinical trial would be
helpful in validating home follow-up as a way to in-
crease INH treatment adherence, but might never be
funded.
When considering the impact of house calls to follow
LTBI patients, the added expense of this approach needs
to be measured. The true cost of home-based follow-up
in our county is difficult to quantify because both com-
munity health workers and public health nurses had
other clinical responsibilities and we do not know the
exact fraction of time that these health workers specific-
ally spent on house calls. An assessment of cost would
need to take into account the time saved by the staff
normally involved in the care of LTBI patients in the
standard clinic-based follow-up. Several other parame-
ters also need to be evaluated. For example, similar to
other TB clinics, we require our patients to return
monthly to the clinic for symptom review and assess-
ment of compliance [27] unless they are followed at
home. Although these monthly clinic visits are effective
in reducing the incidence of severe INH-related hepatitis
[28], they may be too burdensome on the patient and
negatively affect INH adherence. It is possible that only
one component of the house calls, such as medication
delivery via health workers, is sufficient. Until the
shorter, alternate treatment regimens for LTBI become
more affordable and widely available, the strategy
presented here of home-based follow-up of patients on
INH, and the associated cost variables, merit further
exploration and study.
Conclusions
House calls to follow LTBI patients taking INH were
associated with improved treatment completion re-
gardless of patient age, referral reason, place of birth,
or prescribed length of INH therapy. Monthly home-
based follow-up with language-appropriate assess-
ments, delivery of medications, and active tracking of
noncompliant patients could be an effective method
of increasing adherence to INH monotherapy for
LTBI.
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